Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 12/20 | 0.79 |
| ▸ | CA1 | P00915 | 12/20 | 0.79 |
| ▸ | CA2 | P00918 | 12/20 | 0.79 |
| ▸ | CA9 | Q16790 | 12/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | IDE | P14735 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.53 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29897722 | 0.90 | CA12 (0.79) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL12807414 | 0.90 | CA12 (0.75) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL9412855 | 0.89 | CA12 (0.75) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL31578430 | 0.89 | CA12 (0.74) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL14308477 | 0.87 | CA12 (0.72) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL9412854 | 0.86 | CA12 (0.73) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL18400069 | 0.85 | CA12 (0.60) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL21524959 | 0.85 | CA12 (0.78) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL12735647 | 0.85 | CA12 (0.69) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL29782832 | 0.84 | CA12 (0.67) | CA12CA1CA2CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050180945-A1 | Multivalent polymers with chan-terminating binding groups | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-08-18 | — | — | US | disclosed |
| WO-2003099835-A1 | MULTIVALENT POLYMERS WITH CHAIN-TERMINATING BINDING GROUPS | EMORY UNIVERSITY (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050180945-A1 | Multivalent polymers with chan-terminating binding groups | CHIA, SIGLEC7, HDGF | CA12 260/4885CA1 823/4885CA2 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.